Immunotherapeutic agents for the management of BCG refractory non-muscle invasive bladder cancer.
Publication
, Journal Article
Smaldone, MC; Gingrich, JR
Published in: Minerva Urol Nefrol
June 2010
Duke Scholars
Published In
Minerva Urol Nefrol
ISSN
0393-2249
Publication Date
June 2010
Volume
62
Issue
2
Start / End Page
129 / 132
Location
Italy
Related Subject Headings
- Urology & Nephrology
- Urinary Bladder Neoplasms
- Treatment Failure
- Neoplasm Invasiveness
- Immunologic Factors
- Humans
- BCG Vaccine
- Adjuvants, Immunologic
Citation
APA
Chicago
ICMJE
MLA
NLM
Smaldone, M. C., & Gingrich, J. R. (2010). Immunotherapeutic agents for the management of BCG refractory non-muscle invasive bladder cancer. Minerva Urol Nefrol, 62(2), 129–132.
Smaldone, M. C., and J. R. Gingrich. “Immunotherapeutic agents for the management of BCG refractory non-muscle invasive bladder cancer.” Minerva Urol Nefrol 62, no. 2 (June 2010): 129–32.
Smaldone MC, Gingrich JR. Immunotherapeutic agents for the management of BCG refractory non-muscle invasive bladder cancer. Minerva Urol Nefrol. 2010 Jun;62(2):129–32.
Smaldone, M. C., and J. R. Gingrich. “Immunotherapeutic agents for the management of BCG refractory non-muscle invasive bladder cancer.” Minerva Urol Nefrol, vol. 62, no. 2, June 2010, pp. 129–32.
Smaldone MC, Gingrich JR. Immunotherapeutic agents for the management of BCG refractory non-muscle invasive bladder cancer. Minerva Urol Nefrol. 2010 Jun;62(2):129–132.
Published In
Minerva Urol Nefrol
ISSN
0393-2249
Publication Date
June 2010
Volume
62
Issue
2
Start / End Page
129 / 132
Location
Italy
Related Subject Headings
- Urology & Nephrology
- Urinary Bladder Neoplasms
- Treatment Failure
- Neoplasm Invasiveness
- Immunologic Factors
- Humans
- BCG Vaccine
- Adjuvants, Immunologic